학술논문
FDG PET, PET/CT, and breast cancer imaging.
Document Type
Academic Journal
Author
Rosen EL; Department of Radiology, University of Washington Medical Center, Seattle Cancer Care Alliance, 825 Eastlake Ave East, G3-200, Seattle, WA 98109-1023, USA. elrosen@seattlecca.org; Eubank WB; Mankoff DA
Source
Publisher: Radiological Society of North America Country of Publication: United States NLM ID: 8302501 Publication Model: Print Cited Medium: Internet ISSN: 1527-1323 (Electronic) Linking ISSN: 02715333 NLM ISO Abbreviation: Radiographics Subsets: MEDLINE
Subject
Language
English
Abstract
Currently, the clinical role of positron emission tomography (PET) and PET/computed tomography (CT) in patients with breast cancer is to provide additional information in select scenarios in which results of conventional imaging are indeterminate or of limited utility. There is currently no clinical role for fluorodeoxyglucose (FDG) PET in detection of breast cancer or evaluation of axillary lymph nodes, but these are areas of active research. FDG PET is complementary to conventional staging procedures and should not be a replacement for either bone scintigraphy or diagnostic CT. FDG PET and PET/CT have been shown to be particularly useful in the restaging of breast cancer, in evaluation of response to therapy, and as a problem-solving method when results of conventional imaging are equivocal. In these situations, FDG PET often demonstrates locoregional or unsuspected distant disease that affects management. PET has demonstrated a particular capability for evaluation of chemotherapy response in both patients with locally advanced breast carcinoma and those with metastatic disease.
(Copyright RSNA, 2007.)
(Copyright RSNA, 2007.)